NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$445.00
Cat.#: 11699 |
Product Name: Human KRAS Protein |
Size : 10 µg, 50 µg and 100 µg |
Synonyms: C-K-RAS;c-Ki-ras2;CFC2;K-Ras;K-RAS2A;K-RAS2B;K-RAS4A;K-RAS4B;KI-RAS;KRAS1;KRAS2;NS;NS3;RALD;RASK2 |
Target: KRAS |
UNIPROT ID: P01116 |
Description: Recombinant Human KRAS with C-terminal human Fc tag |
Background: This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008] |
Species/Host: HEK293 |
Molecular Weight: The protein has a predicted molecular mass of 47.1 kDa after removal of the signal peptide. The apparent molecular mass of KRAS-hFc is approximately 35-55 kDa due to glycosylation. |
Molecular Characterization: KRAS(Thr2-Cys185) hFc(Glu99-Ala330) |
Purity: The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining. |
Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization. |
Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
Figure 1. Human KRAS Protein, hFc Tag on SDS-PAGE under reducing condition. |